New perspectives in biliary tract cancers
-
Published:2024-09
Issue:
Volume:5
Page:100092
-
ISSN:2949-8198
-
Container-title:ESMO Gastrointestinal Oncology
-
language:en
-
Short-container-title:ESMO Gastrointestinal Oncology
Author:
Goetze T.O.,
Roderburg C.,
Friedrich F.W.ORCID,
Trojan J.ORCID
Reference108 articles.
1. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety;Khankhel;Future Oncol,2022
2. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations;Marcano-Bonilla;Chin Clin Oncol,2016
3. Biliary tract cancer: current medical treatment strategies;Oneda;Cancers,2020
4. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer;Oh;NEJM Evid,2022
5. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial;Kelley;Lancet,2023